ODIX

Founded in 2020 in Belgium, ODIX is transforming the way low back pain (LBP) is treated and prevented. Our long-term vision is to become a category leader in musculoskeletal care, with LumbaCure® setting a new standard in rehabilitation, prevention, and performance support—ultimately improving the quality of life for millions.

LBP is the leading global cause of disability and comes with a massive socio-economic burden. It’s not just about pain—LBP restricts mobility, reduces productivity, and severely impacts quality of life. It affects hundreds of millions worldwide and generates over €135B annually in the U.S. alone in healthcare costs and productivity losses. While prevalence continues to rise, traditional rehabilitation methods haven’t kept pace—leaving a significant gap in effective, scalable, patient-centric care. ODIX addresses this unmet need, with an initial focus on rehabilitation clinics, elite sports centers, and large employers with occupational health programs—markets where we are already seeing traction.

LumbaCure® is a robotic, data-driven seat that delivers guided mobilization of the lumbar spine, combined with an interactive digital interface that boosts patient engagement and provides real-time biofeedbacks. Our roadmap includes expansion into neurorehabilitation and AI-powered personalization to further optimize outcomes.

We’ve built and deployed fully functional pre-commercial units, completed a successful clinical proof-of-concept with 97 patients, and secured strategic industrial partnerships. Our Scientific Advisory Board includes Prof. Deborah Falla, a world-renowned expert in spinal rehabilitation. We have raised €1.1M in equity and non-dilutive public funding and established a robust IP and industrialization strategy.

Our upcoming milestones include additional clinical studies, manufacturing scale-up, and go-to-market execution. We are currently raising €2.1M (completed with 1.2 m from non-dilutive funds) to achieve commercial readiness by 2026. Existing institutional investors have expressed strong interest in following this round.